About Us

We’re pioneering the use of clinically relevant human tissue models for research

Human-centric research is vital for advancing our understanding and innovations in treating human diseases. Humabiologics is at the forefront of enabling laboratories worldwide to transition to a human-derived biomaterial approach to the development of clinically relevant disease models.

Founded in 2018, Humabiologics was the first company devoted to providing native human-derived collagen, gelatin, and extracellular matrix biomaterials for researchers around the globe. We work with a diverse team of tissue bank experts, scientists, engineers, and manufacturers worldwide to provide the highest quality biomaterials with the hope of empowering tomorrow’s innovations.

An industry leader in providing human-derived biomaterials for regenerative medicine

Drug testing has heavily relied on animals and animal biomaterials as the standard approach for developing human therapies. However, the limited success in translating these animal drug models to humans has led to a growing demand for alternatives.

As we look ahead, the future of regenerative medicine and the development of human therapies holds great potential. With advancements in technology and a shift towards more human-centric approaches, we are poised to unlock new frontiers in personalized medicine and revolutionize the way we test and develop treatments.

An industry leader in providing human-derived biomaterials for regenerative medicine

At present, the availability of human-derived biomaterials for regenerative therapies and research is restricted due to lack of stable supply channels, subpar quality biomaterials, and high costs. Humabiologics has taken steps to tackle this problem by partnering with American Association of Tissue Banks (AATB) accredited tissue banks to preserve donated human tissue that was unsuitable for transplantation and use it to create native human-derived biomaterials for researchers to develop life-saving therapies. This approach is founded on treating the donated tissue with utmost respect and dignity, whilst always processing it under the most rigorous quality standards. By collaborating closely with academic and industry institutions, we can provide biomaterials that facilitate the development of translational medicine and bolster the future of regenerative medicine.

Our products can be used independently or in combination with other biomaterials for a broad range of applications in pharmacology, cell culture, and other life sciences fields. Our mission is to promote highly relevant research in regenerative medicine and tissue engineering that will facilitate the translation of medical discoveries from the lab to the clinic, resulting in substantial advancements in patient care.

Awards and Recognition


2022 AZ Inno Madness Champion


Flinn Foundation Bioscience Entrepreneurship

FedEx Small Business Competition
Top 100 of 10,000